HK1146410A1 - 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors - Google Patents

2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors

Info

Publication number
HK1146410A1
HK1146410A1 HK11100565.2A HK11100565A HK1146410A1 HK 1146410 A1 HK1146410 A1 HK 1146410A1 HK 11100565 A HK11100565 A HK 11100565A HK 1146410 A1 HK1146410 A1 HK 1146410A1
Authority
HK
Hong Kong
Prior art keywords
deoxytetrahydrouridines
fluoro
cytidine deaminase
deaminase inhibitors
compounds
Prior art date
Application number
HK11100565.2A
Other languages
English (en)
Inventor
Gregory S Hamilton
Takashi Tsukamoto
Dana V Ferraris
Bridget Duvall
Rena Lapidus
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of HK1146410A1 publication Critical patent/HK1146410A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11100565.2A 2007-10-16 2011-01-20 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors HK1146410A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98039707P 2007-10-16 2007-10-16
PCT/US2008/080163 WO2009052287A1 (en) 2007-10-16 2008-10-16 2 ' -flu0r0-2 ' -deoxytetrahydrouridines as cytidine deaminase inhibitors

Publications (1)

Publication Number Publication Date
HK1146410A1 true HK1146410A1 (en) 2011-06-03

Family

ID=40251685

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100565.2A HK1146410A1 (en) 2007-10-16 2011-01-20 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors

Country Status (39)

Country Link
US (4) US8268800B2 (nl)
EP (2) EP2447272B1 (nl)
JP (2) JP5496899B2 (nl)
KR (1) KR101543049B1 (nl)
CN (1) CN101827856B (nl)
AT (1) ATE548374T1 (nl)
BR (1) BRPI0818672B8 (nl)
CA (1) CA2702274C (nl)
CO (1) CO6270330A2 (nl)
CR (1) CR11427A (nl)
CY (3) CY1112781T1 (nl)
DK (1) DK2207786T3 (nl)
EA (1) EA018757B1 (nl)
EC (1) ECSP10010095A (nl)
ES (2) ES2384011T3 (nl)
FI (2) FIC20230040I1 (nl)
FR (2) FR23C1051I1 (nl)
GT (1) GT201000088A (nl)
HK (1) HK1146410A1 (nl)
HR (1) HRP20120419T1 (nl)
HU (2) HUS2300045I1 (nl)
IL (1) IL204732A (nl)
JO (1) JO2778B1 (nl)
ME (1) ME00997B (nl)
MX (1) MX2010004109A (nl)
MY (1) MY147970A (nl)
NI (1) NI201000055A (nl)
NL (1) NL301256I2 (nl)
NO (2) NO2023048I1 (nl)
NZ (1) NZ584229A (nl)
PL (1) PL2207786T3 (nl)
PT (1) PT2207786E (nl)
RS (1) RS52323B (nl)
SA (1) SA08290661B1 (nl)
SI (1) SI2207786T1 (nl)
TW (1) TWI445539B (nl)
UA (1) UA99476C2 (nl)
WO (1) WO2009052287A1 (nl)
ZA (1) ZA201002178B (nl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20100055047A1 (en) * 2008-08-26 2010-03-04 Yiyu Zou Methods for treating bronchial premalignancy and lung cancer
KR20110104074A (ko) 2008-12-23 2011-09-21 파마셋 인코포레이티드 퓨린 뉴클레오시드의 합성
JP5684787B2 (ja) * 2009-04-06 2015-03-18 大塚製薬株式会社 シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
UY32546A (es) * 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
TWI477508B (zh) * 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CA2794671C (en) 2010-03-31 2018-05-01 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
CN106166160A (zh) 2011-09-16 2016-11-30 吉利德制药有限责任公司 用于治疗hcv的组合物
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20140212491A1 (en) 2013-01-31 2014-07-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP4005560A1 (en) 2013-08-27 2022-06-01 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
KR102272773B1 (ko) * 2013-10-29 2021-07-02 오츠카 세이야쿠 가부시키가이샤 2'-데옥시-2',2'-디플루오로테트라하이드로우리딘의 합성 경로
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
HUE061382T2 (hu) 2014-08-22 2023-06-28 Celgene Corp Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
EP3960182A1 (en) * 2015-12-03 2022-03-02 Epidestiny, Inc. Compositions containing decitabine, 5-azacytidine and tetrahydrouridine and uses thereof
WO2017158396A1 (en) * 2016-03-16 2017-09-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Cytidine deaminase inhibitors for the treatment of pancreatic cancer
KR20200118827A (ko) 2018-02-02 2020-10-16 마베릭스 온콜로지, 잉크. 젬시타빈 모노포스페이트의 소분자 약물 컨쥬게이트
US11224610B2 (en) * 2018-09-19 2022-01-18 Otsuka Pharmaceutical Co., Ltd. Low dose combination CDA substrate drug/cedazuridine with extended administration
EP3868774A4 (en) * 2018-10-19 2023-05-10 Interoligo Corporation MODIFIED NUCLEIC ACID WITH IMPROVED TREATMENT EFFICIENCY AND ANTI-CANCER PHARMACEUTICAL COMPOSITION THEREOF
WO2020080912A1 (ko) * 2018-10-19 2020-04-23 인터올리고 주식회사 치료 효능을 개선한 핵산 변형체 및 이를 포함하는 항암용 약학 조성물
AU2020363412A1 (en) * 2019-10-08 2022-04-07 Otsuka Pharmaceutical Co., Ltd. 2'-deoxy-2',2'-difluorotetrahydrouridines with high purity and methods of making the same
AU2021227888A1 (en) * 2020-02-25 2022-07-14 Otsuka Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms
CA3211943A1 (en) * 2021-03-26 2022-09-29 Yogen Saunthararajah Treatment of rna virus infection with a cytidine deaminase inhibitor
WO2022254457A1 (en) * 2021-05-29 2022-12-08 Msn Laboratories Private Limited, R&D Center An improved process for the preparation of (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl) oxolan-2-yl]-4-hydroxy-1,3-diazinan-2one and its intermediate compounds
CA3236051A1 (en) 2021-10-19 2023-04-27 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
WO2023076332A1 (en) * 2021-11-01 2023-05-04 St. John's University Injectable liquid pharmaceutical compostion containing gemcitabine and a cytidine deaminase inhibitor
US20230271996A1 (en) * 2021-12-25 2023-08-31 Scinopharm Taiwan, Ltd. Process for preparing cedazuridine
WO2024047394A1 (en) 2022-08-31 2024-03-07 Otsuka Pharmaceutical Co., Ltd. Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4210638A (en) * 1978-03-17 1980-07-01 Pcr, Inc. Antiviral composition and method of treating virus diseases
US4275057A (en) 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
WO1985001871A1 (en) 1983-10-26 1985-05-09 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
EP0184365B1 (en) 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
EP0543976A4 (en) 1991-04-23 1993-11-10 Oglevee, Ltd. In vitro leaf petiole multiplication of pelargoniums
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
AU664948B2 (en) 1993-02-23 1995-12-07 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) * 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) * 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
AU5300396A (en) * 1995-03-01 1996-09-18 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
AU3354500A (en) 1999-03-01 2000-09-21 Halogenetics, Inc. Dramatic simplification of a method to treat neoplastic disease by radiation
MXPA02002088A (es) 1999-08-26 2003-09-22 Aortech Internat Plc Mejoras en relacion al posicionamiento del cateter.
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
CN100368422C (zh) 2000-11-29 2008-02-13 三井化学株式会社 L-核酸衍生物及其合成方法
EP1353693B1 (en) 2001-01-16 2005-03-16 Glaxo Group Limited Pharmaceutical combination containing a 4-quinazolineamine and paclitaxel, carboplatin or vinorelbine for the treatment of cancer
EP1387850A2 (en) 2001-05-18 2004-02-11 Rakesh Kumar Antiviral nucleosides
CA2454147C (en) * 2001-07-31 2013-05-21 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Inhibitor of dna methylation
NZ534811A (en) 2002-02-14 2007-07-27 Pharmasset Inc Modified fluorinated nucleoside analogues
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
US8158770B2 (en) 2004-05-06 2012-04-17 University Of Rochester Content dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN101076536A (zh) 2004-07-30 2007-11-21 药华医药股份有限公司 β－核苷的立体选择性合成
JP2007522151A (ja) 2004-12-08 2007-08-09 シコール インコーポレイティド ジフルオロヌクレオシド及びその調製方法
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
UY32546A (es) 2009-04-06 2010-10-29 Eisai Inc Composiciones y metodos para tratar cancer
JP5684787B2 (ja) 2009-04-06 2015-03-18 大塚製薬株式会社 シチジンベースの抗新生物薬とシチジンデアミナーゼ阻害薬との組合せ、および癌の治療におけるその使用
TWI477508B (zh) 2009-04-06 2015-03-21 Otsuka Pharma Co Ltd 用以治療癌症之組成物及方法
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer

Also Published As

Publication number Publication date
JP2011500713A (ja) 2011-01-06
GT201000088A (es) 2012-03-13
EP2447272A1 (en) 2012-05-02
US20090137521A1 (en) 2009-05-28
IL204732A (en) 2013-07-31
HRP20120419T1 (hr) 2012-07-31
EA201000642A1 (ru) 2010-10-29
TWI445539B (zh) 2014-07-21
TW200924786A (en) 2009-06-16
MX2010004109A (es) 2010-08-10
BRPI0818672A2 (pt) 2015-04-14
KR20100091978A (ko) 2010-08-19
FR23C1051I1 (fr) 2024-01-26
NZ584229A (en) 2012-06-29
RS52323B (en) 2012-12-31
EP2447272B1 (en) 2017-02-01
UA99476C2 (en) 2012-08-27
HUS2300045I1 (hu) 2024-01-28
DK2207786T3 (da) 2012-06-18
CN101827856A (zh) 2010-09-08
WO2009052287A1 (en) 2009-04-23
US20150210730A1 (en) 2015-07-30
EP2207786B1 (en) 2012-03-07
JP5496899B2 (ja) 2014-05-21
US8951987B2 (en) 2015-02-10
SI2207786T1 (sl) 2012-10-30
BRPI0818672B1 (pt) 2020-10-20
CY2023028I1 (el) 2024-02-16
AU2008312435A1 (en) 2009-04-23
ZA201002178B (en) 2011-05-25
ECSP10010095A (es) 2010-07-30
PL2207786T3 (pl) 2012-09-28
HUS2300044I1 (hu) 2024-01-28
NI201000055A (es) 2010-08-13
CR11427A (es) 2010-08-16
JP5859588B2 (ja) 2016-02-10
MY147970A (en) 2013-02-28
BRPI0818672B8 (pt) 2021-05-25
IL204732A0 (en) 2010-11-30
ES2384011T3 (es) 2012-06-28
US20140186335A1 (en) 2014-07-03
CY2023029I1 (el) 2024-02-16
ATE548374T1 (de) 2012-03-15
FIC20230039I1 (fi) 2023-12-22
CA2702274A1 (en) 2009-04-23
KR101543049B1 (ko) 2015-08-07
NL301256I1 (nl) 2024-01-03
AU2008312435B2 (en) 2014-04-17
NL301256I2 (nl) 2024-01-11
FIC20230040I1 (fi) 2023-12-22
FR23C1052I1 (fr) 2024-01-26
EP2207786A1 (en) 2010-07-21
JP2014177455A (ja) 2014-09-25
NO2023048I1 (en) 2023-12-21
EA018757B1 (ru) 2013-10-30
US9567363B2 (en) 2017-02-14
SA08290661B1 (ar) 2012-06-10
ES2616566T3 (es) 2017-06-13
PT2207786E (pt) 2012-05-28
NO2023047I1 (no) 2023-12-21
US20120289475A1 (en) 2012-11-15
CY1112781T1 (el) 2016-02-10
JO2778B1 (en) 2014-03-15
CN101827856B (zh) 2013-02-06
CO6270330A2 (es) 2011-04-20
ME00997B (me) 2012-10-20
AU2008312435A8 (en) 2014-07-24
US8268800B2 (en) 2012-09-18
CA2702274C (en) 2015-12-29
US8618075B2 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
HK1146410A1 (en) 2'-fluoro-2'-deoxytetrahydrouridines as cytidine deaminase inhibitors
TW200634023A (en) Amide prodrug of gemcitabine, compositions and use thereof
EP2332951A3 (en) 6-modified bicyclic nucleic acid analogs
UA97502C2 (ru) Кристаллическая твердая основа разагилина
WO2007002204A3 (en) Pyrosequencing methods and related compostions
EP2061476A4 (en) COMPOSITIONS WITH CDP-CHOLINE AND METHOD OF USE THEREOF
WO2008013589A3 (en) Treatment of ras-expressing tumors
WO2008049116A3 (en) Substituted indoles
WO2008127364A3 (en) Antiviral compounds and use thereof
MY142105A (en) Leukotriene biosynthesis inhibitors
TW200740814A (en) Compounds
WO2009073506A3 (en) Nucleoside prodrugs and uses thereof
WO2006060189A3 (en) Curable silicone compositions incorporating a fluorescent detection system
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
TW200716130A (en) Purified form of tanaproget
WO2007149891A3 (en) Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
WO2008107771A3 (en) 2',3'-di-o-acyl-5-fluoronucleosides
MX2009009074A (es) Macrolidos basados en eritromicina.
DE502006003012D1 (nl)
JO3046B1 (ar) اشكال متعددة من 7- )] 3-كلورو-6و11-ثنائي هيدرو -6-ميثيل ثنائي بنزو [1, 2][f,c] ثيازبين-11-يل)امينو[ حمض هباتونك S,S- ثنائي أوكسيد وطرق لتصنيعها و استخدامها.
WO2006084116A3 (en) Amine derivative containing compositions and methods for the treatment of viral infections related to the etiology of cancer
FR2907448B1 (fr) Composition de brasure et procede d'assemblage par brasage utilisant cette composition
CL2008000678A1 (es) Compuestos derivados de 4,5-bis-alquilsulfanil-[1,3]ditiol-2-tiona o 4,5-bis-alquilsulfanil-[1,3]ditiol-2-ona; composicion de lubricante; uso de dicha composicion; y metodo.
WO2008097341A3 (en) Antiviral compounds and use thereof

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE ADDRESS OF PROPRIETOR FROM 9, KANDA-TSUKASAMACHI 2-CHOME, CHIYODA-KU, TOKYO, 101-8535 JAPAN. P, JAPAN TO 9, KANDA- TSUKASAMACHI 2-CHOME, CHIYODA-KU, TOKYO 101-8535, JAPAN